These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 1725104)

  • 1. Acute phase reactants and circulating immune complexes in patients with ovarian carcinoma.
    Dobryszycka W; Gerber J; Zuwała-Jagiełło J; Ujec M
    Arch Immunol Ther Exp (Warsz); 1991; 39(1-2):41-50. PubMed ID: 1725104
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical usefulness of serum acute-phase reactants in patients with ovarian tumors.
    Warwas M; Dobryszycka W; Gerber J; Pietkiewicz A
    Neoplasma; 1981; 28(4):485-90. PubMed ID: 7290269
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum haptoglobin, CA 125 and interleukin 6 levels in malignant and non-malignant tumors of the ovary.
    Dobryszycka W; Katnik-Prastowska I; Gerber J; Lemańska K; Utko K; Rozdolski K
    Arch Immunol Ther Exp (Warsz); 1999; 47(4):229-36. PubMed ID: 10483871
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Sequential determination of circulating immune complexes in ovarian tumors].
    Beaufort F; Auner H; Lahousen M
    Wien Med Wochenschr; 1986 Jul; 136(13):317-22. PubMed ID: 3765649
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lipid associated sialic acid in plasma in patients with advanced carcinoma of the ovaries.
    Vardi JR; Tadros GH; Malhotra C; Charney T; Shebes M; Foemmel R
    Surg Gynecol Obstet; 1989 Apr; 168(4):296-301. PubMed ID: 2928903
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Serum lipid-associated sialic acid (LSA) in diagnosing and monitoring ovarian cancer].
    Yue K; Bian M; Zhu D; Liu W; Siu S
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 1995 Apr; 17(2):128-32. PubMed ID: 7656393
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Plasma lipid-associated sialic acid and serum CA 125 as indicators of disease status with advanced ovarian cancer.
    Vardi JR; Tadros GH; Foemmel R; Shebes M
    Obstet Gynecol; 1989 Sep; 74(3 Pt 1):379-83. PubMed ID: 2761915
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum sErbB1 and epidermal growth factor levels as tumor biomarkers in women with stage III or IV epithelial ovarian cancer.
    Baron AT; Lafky JM; Boardman CH; Balasubramaniam S; Suman VJ; Podratz KC; Maihle NJ
    Cancer Epidemiol Biomarkers Prev; 1999 Feb; 8(2):129-37. PubMed ID: 10067810
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CA 125, NB/70K, and lipid-associated sialic acid in monitoring uterine papillary serous carcinoma.
    Tseng PC; Sprance HE; Carcangiu ML; Chambers JT; Schwartz PE
    Obstet Gynecol; 1989 Sep; 74(3 Pt 1):384-7. PubMed ID: 2761916
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A case control study of glycoprotein status in ovarian carcinoma.
    Aranganathan S; Senthil K; Nalini N
    Clin Biochem; 2005 Jun; 38(6):535-9. PubMed ID: 15885233
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Cytokeratin tumor markers in ovarian carcinoma: tissue polypeptide specific antigen (TPS) and M3/M21].
    Hefler L; Tempfer C; Häusler G; Heinzl H; Kainz C
    Wien Klin Wochenschr; 1998 Oct; 110(18):635-41. PubMed ID: 9816636
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Clinical significance of serum ferritin and acute phase reactant proteins levels in patients with cervical cancer].
    Xie JF
    Zhonghua Fu Chan Ke Za Zhi; 1991 Mar; 26(2):92-4, 124. PubMed ID: 1713541
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A sequential study of humoral factors in ovarian neoplasms.
    Gupta SC; Agarwal J; Singh PA; Mehdiratta NK; Keswani NK
    Indian J Pathol Microbiol; 1994 Jul; 37(3):319-26. PubMed ID: 7814065
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative analysis of CA125, tissue polypeptide specific antigen, and soluble interleukin-2 receptor alpha levels in sera, cyst, and ascitic fluids from patients with ovarian carcinoma.
    Sedlaczek P; Frydecka I; Gabryś M; Van Dalen A; Einarsson R; Harłozińska A
    Cancer; 2002 Nov; 95(9):1886-93. PubMed ID: 12404282
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [The value of CA 125 determination in the serum of patients with ovarian cancer].
    Bartel U; Johannsen B; Elling D
    Zentralbl Gynakol; 1989; 111(5):301-9. PubMed ID: 2728673
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Proteomic tracking of serum protein isoforms as screening biomarkers of ovarian cancer.
    Ahmed N; Oliva KT; Barker G; Hoffmann P; Reeve S; Smith IA; Quinn MA; Rice GE
    Proteomics; 2005 Nov; 5(17):4625-36. PubMed ID: 16220531
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Tumor markers in the monitoring of ovarian cancer].
    Xu SX
    Zhonghua Fu Chan Ke Za Zhi; 1990 Nov; 25(6):345-7, 383. PubMed ID: 2282861
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [The diagnostic value of the assay of lactate dehydrogenese combined with other tumor markers in ovarian cancer].
    Tang BJ; Li L; Xu J
    Zhonghua Fu Chan Ke Za Zhi; 1994 Jun; 29(6):336-9, 381. PubMed ID: 8001406
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preoperative serum tetranectin, CA125 and menopausal status used as single markers in screening and in a risk assessment index (RAI) in discriminating between benign and malignant ovarian tumors.
    Begum FD; Høgdall E; Kjaer SK; Blaakaer J; Christensen IJ; Christensen L; Høgdall C
    Gynecol Oncol; 2009 May; 113(2):221-7. PubMed ID: 19261323
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Shed membrane fragment-associated markers for endometrial and ovarian cancers.
    Taylor DD; Lyons KS; Gerçel-Taylor C
    Gynecol Oncol; 2002 Mar; 84(3):443-8. PubMed ID: 11855885
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.